An organization’s ability to shift course used to be a badge of honor; now, it’s a mark of exhausting and constant change.

The Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for depemokimab for asthma with type 2 inflammation ... This extended half-life allows ...

Your pension isn’t just about how much you’ve saved – it’s about how you draw it down. Understanding the real impact of your ...

Once people set up their retirement plan contributions at work, they are often put on the back burner. Out of sight, out of ...

The high plasma concentrations with prolonged systemic exposure were consistent with the reported half-life for semaglutide ... later this year First GLP-2 Peptide Tablets for Short Bowel Syndrome ...

In April 2024, Entera announced that the Journal of Bone and Mineral Research (JBMR) published EB613 placebo controlled Phase 2 Trial results, highlighting its dual mechanism of action and rapid ...

The high plasma concentrations with prolonged systemic exposure were consistent with the reported half-life for semaglutide (Rybelsus ... single dose pharmacokinetic study in rodents. Oral GLP-2 ...

Operator Good afternoon, ladies and gentlemen, and welcome to the INOVIO Pharmaceuticals fourth quarter 2024 financial results conference call. At this time, all lines are in listen-only mode.

Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and proteins replacement therapies, today reported financial results and key ...

Recent studies have demonstrated survival rates above 90% after 2 years of treatment with guselkumab ... Pharmacokinetic models indicate it has a half-life of 18.1 days, providing insight into its ...

It has been shown in clinical studies to be successful in targeting FXIIa; furthermore, it has an extended half-life that makes once monthly subcutaneous ... that require more frequent dosing. A phase ...